Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Alicia K. Morgans, MD
Advertisement
Articles by Alicia K. Morgans, MD
CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology Congress to talk about the rationale for analyzing the financial impact of cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.
In this interview ahead of ASCO 2017 we discuss the physical and cognitive effects of androgen deprivation therapy in older men treated for prostate cancer.
Advertisement
Latest Updated Articles
Addressing Physical, Cognitive Effects of ADT in Prostate Cancer PatientsPublished: May 31st 2017 | Updated:
Alicia Morgans, MD, MPH, on the Rationale for Examining the Clinical and Cost Impact of Cabazitaxel in mCRPCPublished: October 11th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
3
Muscle RNome Analysis Reveals 2 Molecular Subtypes Associated With Cancer Cachexia
4
How Can Oncology Staffing Shortages Be Remedied?
5
